✦ LIBER ✦

Open-label, phase I dose-escalation study of sodium selenate, a novel activator of PP2A, in patients with castration-resistant prostate cancer

✍ Scribed by Corcoran, N M; Hovens, C M; Michael, M; Rosenthal, M A; Costello, A J

Book ID: 110000587
Publisher: Nature Publishing Group
Year: 2010
Tongue: English
Weight: 333 KB
Volume: 103
Category: Article
ISSN: 0007-0920
DOI: 10.1038/sj.bjc.6605798

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Open-label, clinical phase I studies of

Open-label, clinical phase I studies of tasquinimod in patients with castration-resistant prostate cancer

✍ Häggman, M; Ahlgren, G; Nordle, Ö; Björk, A; Damber, J-E; Bratt, O 📂 Article 📅 2009 🏛 Nature Publishing Group 🌐 English ⚖ 371 KB

A phase I/II dose-escalation study of ex

A phase I/II dose-escalation study of exisulind and docetaxel in patients with hormone-refractory prostate cancer

✍ Christopher W. Ryan; Walter M. Stadler; Nicholas J. Vogelzang 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 101 KB

A phase I study of oral panobinostat alo

A phase I study of oral panobinostat alone and in combination with docetaxel in patients with castration-resistant prostate cancer

✍ Dana Rathkopf; Bryan Y. Wong; Robert W. Ross; Aseem Anand; Erika Tanaka; Margare 📂 Article 📅 2010 🏛 Springer 🌐 English ⚖ 378 KB

Phase I rapid dose-escalation study of A

Phase I rapid dose-escalation study of AGS-1C4D4, a human anti-PSCA (prostate stem cell antigen) monoclonal antibody, in patients with castration-resistant prostate cancer: a PCCTC trial

✍ Emmanuel S. Antonarakis; Michael A. Carducci; Mario A. Eisenberger; Samuel R. De 📂 Article 📅 2011 🏛 Springer 🌐 English ⚖ 316 KB

A Phase I, open label, dose ranging tria

A Phase I, open label, dose ranging trial of intravenous bolus zoledronic acid, a novel bisphosphonate, in cancer patients with metastatic bone disease

✍ James R. Berenson; Robert Vescio; Kathryn Henick; Carol Nishikubo; Matthew Retti 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 127 KB 👁 2 views

Phase I, open-label, single-center, mult

Phase I, open-label, single-center, multiple-dose, dose-escalation clinical study of SUO11248 (Sunitinib) in subjects with high-risk prostate cancer who have elected to undergo radical prostatectomy

✍ Allan J. Pantuck; Nazy Zomorodian; Arie S. Belldegrun 📂 Article 📅 2007 🏛 Springer 🌐 English ⚖ 66 KB